Efficacy and Safety of Adalimumab for Paediatric Crohn’s Disease: A Systematic Review-Reference-Cited by-同舟云学术

Efficacy and Safety of Adalimumab for Paediatric Crohn’s Disease: A Systematic Review

Published:2016-03-19 Issue:10 Volume:10 Page:1237-1244
ISSN:1873-9946
Container-title:Journal of Crohn's and Colitis
language:en
Short-container-title:ECCOJC

Author:

Dziechciarz Piotr,Horvath Andrea,Kierkuś Jaroslaw

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,General Medicine

Link

http://academic.oup.com/ecco-jcc/article-pdf/10/10/1237/13746259/jjw077.pdf

Reference30 articles.

1. Biologic therapies in inflammatory bowel disease

2. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease

3. Off-label use of medicine in pediatrics

4. Moga C , Guo B Schopflocher D Harstall C. Development of a quality appraisal tool for case series studies using a modified Delphi technique. Institute of Health Economics website. http://www.ihe.ca/documents/Case%20series%20studies%20using%20a%20modified%20Delphi%20technique.pdf

5. Safety and Efficacy of Adalimumab for Moderate to Severe Crohn's Disease in Children

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adverse Event Profiles of Adalimumab in Children: A Disproportionality Analysis;Pharmaceuticals;2024-08-05

2. Antagonistas del factor de necrosis tumoral (TNF) en la enfermedad inflamatoria intestinal pediátrica: Una revisión sistemática;Medicina Clínica;2023-06

3. Tumour necrosis factor (TNF) antagonist therapy for paediatric inflammatory bowel disease: A systematic review;Medicina Clínica (English Edition);2023-06

4. Efficacy of early biologic therapy versus late/conventional therapy in children and adolescents with Crohn’s disease: A systematic review and meta-analysis;Saudi Journal of Gastroenterology;2023

5. Anti-TNF Therapies Other Than Infliximab for the Treatment of Pediatric Inflammatory Bowel Disease;Pediatric Inflammatory Bowel Disease;2023